Granules India Ltd - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Granules India Limited issues voluntary recall of one batch of Naproxen Sodium 220mg tablets13-09-2021
13-09-2021
Drug firms Granules India, Jubilant Cadista recall products in US market
Jubilant Cadista is a fully-owned subsidiary of Cadista Holdings Inc, which is a part of the Noida-based Jubilant Life Sciences Company.12-09-2021
GRANULES INDIA LTD.-$ - 532482 - Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Granules received licence from DRDO to manufacture and market of 2-DG.02-09-2021
Granules India gets Health Canada nod to market arthritis tablets
The company will soon launch the product in Canadian market30-08-2021
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Granules India Limited Received Approval from the Health Canada for Acetaminophen Extended-Release Tablets30-08-2021
Granules India Ltd - 532482 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate16-08-2021
Granules India Ltd - 532482 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of the Analyst/Investor Meeting11-08-2021
GRANULES INDIA LTD.-$ - 532482 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Granules India Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here06-08-2021
GRANULES INDIA LTD.-$ - 532482 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings and details of the voting results of the 30th Annual General Meeting along with Scrutinizer''s report.06-08-2021
Buy Granules India; target of Rs 430: ICICI Direct
ICICI Direct is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 430 in its research report dated July 29, 2021.04-08-2021